BOSTON--(BUSINESS WIRE)--PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage bioelectronic medicine company developing non-invasive systems for the treatment of patients with neuromotor disorders, has named Ole Isacson, M.D., Ph.D., to the Company’s Scientific Advisory Board.
Dr. Isacson is Professor of Neurology (Neuroscience) at Harvard Medical School and Professor of Neurology at Massachusetts General Hospital. He is the founding Director of the Neuroregeneration Research Institute at McLean Hospital/Harvard Medical School. Over the past two decades, his laboratory has grown into an internationally recognized academic research center for Parkinson’s disease and related disorders. His scientific models and studies of new concepts for therapeutic treatment have resulted in many new findings and clinical trials for neurodegenerative disorders. In addition to his academic research, Dr. Isacson has also previously served as Chief Scientific Officer of Pfizer’s Neuroscience Research Unit.
“I am very excited to be joining PathMaker’s Scientific Advisory Board,” said Dr. Isacson. “The company’s use of non-invasive neuromodulation technology could drastically change how various chronic neurodegenerative disorders are treated and fill a tremendous unmet need that exists for these patients.”
“We are very pleased to have Dr. Isacson with his extensive expertise in the field of neuroscience contributing to our Scientific Advisory Board,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “His academic research and knowledge of the field coupled with his industry perspective will be invaluable as we work to rapidly advance our first-in-class neuromodulation products to treat patients with chronic conditions such as spasticity and paralysis.”
Dr. Isacson earned his Medical Bachelor and Doctor of Medicine (a research doctoral degree in Medical Neurobiology) from the University of Lund in Sweden. He completed a post-doctoral fellowship at Cambridge University in England before joining Harvard Medical School. In addition to his academic posts, Dr. Isacson was a member of the Advisory Board for the Harvard NeuroDiscovery Center and served as the Executive Director of the National Institute of Neurological Disorders and Stroke Parkinson’s Disease Induced Pluripotent Stem (iPS) Cell Research Consortium. He has been honored by a number of awards in recent years, including the Fernstrom Foundation Research Scholarship Award (Lund University), the Royal Swedish Academy of Sciences: Lindahl Young Investigator Award, the Bernard Sanberg Memorial Prize for Brain Repair (ASNTR), the Druker Memorial Lecture Award (Boston) and The Kellermann Family Memorial Award , Maryland Stem Cell Foundation. He is a member of the Michael J. Fox Foundation Scientific Advisory Board and the Scientific Advisory Council. He is the Emeritus Editor in Chief of Molecular and Cellular Neuroscience and has published more than 300 original peer-reviewed scientific articles and reviews. Prof. Isacson was elected as a fellow member to the American Association for the Advancement of Science (AAAS) in 2013.
About PathMaker Neurosystems Inc.
PathMaker Neurosystems is
a clinical-stage bioelectronic medicine company developing breakthrough
non-invasive systems for the treatment of patients with chronic
neuromotor conditions. With offices in Boston (U.S.) and Paris (France),
we are collaborating with world-class research institutions to rapidly
bring to market disruptive products for treating spasticity, paralysis
and muscle weakness. More than 48 million patients in the US, Europe and
China suffer disabilities due to stroke, cerebral palsy, multiple
sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s
disease and other neurological disorders. At PathMaker, we are opening
up a new era of non-invasive neurotherapy for patients suffering from
chronic neuromotor conditions. For more information, please visit the
company website at www.pmneuro.com.
